Indian regulators seize more than 260 counterfeit Mounjaro pens

Drug control officials in Haryana, India, seized more than 260 suspected counterfeit pens of Mounjaro, Eli Lilly's tirzepatide drug for diabetes and weight loss, and arrested two people accused of making and selling them ^[1][2]. The pens were recovered from a vehicle on the outskirts of New Delhi on a Saturday in April, and came in strengths ranging from 2.5 mg to 15 mg ^[1][2].

According to Drug Control Officer Amandeep Chauhan, the main accused had no pharmaceutical license and made the products at a private property ^[1]. Officials said the peptides used to make the fake pens were sourced from vendors on the Chinese e-commerce platform Alibaba, and investigators recovered large quantities of raw materials along with locally made Mounjaro packaging labels from the property ^[1]. The Economic Times, citing a separate but related account of the same seizure, reported the raid happened near a shopping area in Gurgaon, where officials stopped a car carrying the pens in ice boxes and detained a passenger who named another man as the owner of the shipment ^[2]. That report put the market value of the seized consignment at more than 70 lakh rupees, or about $75,000, based on an estimated price of 28,000 rupees per pen ^[2]. Reuters reported the raw materials alone were valued at around 7 million rupees, or about $75,000 ^[1]. Neither source could independently confirm all details of how the operation worked.

Both accounts describe the same red flags: the pens had not been stored at the required 2 to 8 degrees Celsius, and they showed mismatches in font size and other label details compared with genuine Mounjaro packaging ^[1][2]. Officials said these discrepancies raised suspicion that the products were spurious, and samples were sent to government laboratories for confirmation ^[1]. The Economic Times reported the two arrested men were selling the pens on the online marketplace IndiaMART at a price roughly 27% below the cost of the genuine drug ^[1]. Authorities invoked provisions of India's Drugs and Cosmetics Act covering spurious drugs, and the two men arrested at the scene were placed in judicial custody pending further investigation ^[2].

Alibaba and IndiaMART did not immediately respond to requests for comment from Reuters ^[1]. Eli Lilly said in a statement that it takes patient safety extremely seriously and welcomes the regulatory action, adding that it is supporting the investigation ^[1].

Why it matters for patients

This seizure happened in India, not the United States, and the pens were sold through an Indian online marketplace, not through US pharmacies ^[1][2]. But the case illustrates a pattern regulators worldwide have flagged: counterfeiters can obtain peptide raw materials through international e-commerce platforms and assemble products that mimic brand-name packaging closely enough to fool casual inspection ^[1]. The pens in this case failed on basic markers, including improper cold storage and label inconsistencies, which are exactly the kinds of things a buyer might not notice without close comparison ^[1][2].

Tirzepatide, the active ingredient in Mounjaro, requires refrigeration and precise dosing, and products made outside licensed manufacturing conditions carry unknown risks because their contents and purity have not been verified ^[1][2]. For US readers, the case is a reminder that GLP-1 drugs bought outside licensed pharmacy channels, including from overseas websites or unverified online sellers, cannot be assumed to match the labeled dose or ingredients ^[1][2].

What happens next

Indian officials said samples from the seized pens were sent to government laboratories for confirmation testing, and the investigation into the broader supply chain, including where the raw materials originated and how the finished products were distributed, is ongoing ^[1][2]. The two arrested men remained in judicial custody as of the reporting ^[1][2]. No timeline for laboratory results or further arrests was given in the available reporting.